NCT05651828View on ClinicalTrials.gov

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Advanced Basal Cell Carcinoma
Interventions
DRUG

Vismodegib 150 MG Oral Capsule

Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.

Trial Locations (1)

33617

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER